TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30514319

Group type: EXPERIMENTAL
Intervention: High levels of dihydrotestosterone in males
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: High levels of 17-OH-progesterone in males
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Testosterone levels in males
Number of subjects: 285
Study: 27035604

Group type: EXPERIMENTAL
Intervention: SPS‐DECTA
Number of subjects: 80

Group type: COMPARATOR
Intervention: DECTA
Number of subjects: 80
Study: 24623508

Group type: COMPARATOR
Intervention: M1-M1 tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PM-M1 tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All sessions (M1-M1, PM-M1, Sham)
Number of subjects: 0
Study: 24624878

Group type: EXPERIMENTAL
Intervention: Abnormal savda munziq (ASMq) at 0.1-1.0 mg/ml
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-Fu)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 6
Study: 20798196

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Letrozole (L + Let)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Letrozole plus placebo (Let)
Number of subjects: 219
Study: 17543540

Group type: EXPERIMENTAL
Intervention: Ownership of objects (self-owned vs. other-owned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving items (acting on items)
Number of subjects: 0
Study: 15721728

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 12972100

Group type: EXPERIMENTAL
Intervention: Intravenous platelet glycoprotein IIb/IIIa antagonists
Number of subjects: 20186
Study: 11910657

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and oral medroxyprogesterone acetate 10 mg/day during the last 12 days of the month
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clodronate - oral clodronate 400 mg/day for 1 month out of every 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcitonin - nasal spray 100 IU/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clodronate plus Calcitonin - oral clodronate 400 mg/day for 1 month out of every 3 months plus calcitonin nasal spray 100 IU/day
Number of subjects: 100
Study: 9399465

Group type: EXPERIMENTAL
Intervention: PTA alone
Number of subjects: 34

Group type: COMPARATOR
Intervention: PTA with Wallstent
Number of subjects: 34
Study: 8186713

Group type: EXPERIMENTAL
Intervention: Intermittent low dosage schedule of Prednisolone at 0.75 mg kg‐1 day‐1 for 10 days at the beginning of each calendar month
Number of subjects: 32
Study: 3531731

Group type: EXPERIMENTAL
Intervention: New membrane oxygenator (LPM 50)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bubble oxygenator
Number of subjects: 30
Study: 28361171

Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite 2% gel toothpaste fluoride free
Number of subjects: 105

Group type: COMPARATOR
Intervention: fluoride gel toothpaste
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 26910438

Group type: EXPERIMENTAL
Intervention: Music with noise-canceling headphones (NCHs) during SWL
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Music with non-noise-canceling headphones (non-NCHs) during SWL
Number of subjects: 89

Group type: COMPARATOR
Intervention: No headphones and music (Control group)
Number of subjects: 89
Study: 24965700

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 269
Study: 22672941

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both PRT and CON
Number of subjects: 14
Study: 21252486

Group type: EXPERIMENTAL
Intervention: Hypothermia therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 0
Study: 18352982

Group type: EXPERIMENTAL
Intervention: Internal imagery training for 72 minutes over six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular workouts (control group)
Number of subjects: 0
Study: 15544421

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acids mixture without tryptophan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (same mixture with tryptophan)
Number of subjects: 20
Study: 11877686

Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin therapy (WASA)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Aspirin therapy alone (ASA)
Number of subjects: 831
Study: 9561883

Group type: EXPERIMENTAL
Intervention: Preventive practices (diet and drugs)
Number of subjects: 3863

Group type: EXPERIMENTAL
Intervention: Perceptions of AMI triggers
Number of subjects: 3863

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 3863

Group type: EXPERIMENTAL
Intervention: Preventive practices usage
Number of subjects: 3863
Study: 7625118

Group type: EXPERIMENTAL
Intervention: 50 micrograms rgp160 vaccine adjuvanted in alum and deoxycholate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 micrograms rgp160 immunization
Number of subjects: 10
Study: 3395106

Group type: EXPERIMENTAL
Intervention: 4 g every 6 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 g every 8 h
Number of subjects: 12
Study: 29268939

Group type: EXPERIMENTAL
Intervention: Stepwise group (SG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comprehensive group (CG)
Number of subjects: 20
Study: 28595862

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 627

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 627
Study: 26122230

Group type: EXPERIMENTAL
Intervention: High resolution magnetic resonance angiography (MRA)
Number of subjects: 200
Study: 23830165

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic foot pumps (IPF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no IPF)
Number of subjects: 24
Study: 20652275

Group type: EXPERIMENTAL
Intervention: Thiamine (150 mg, orally, once daily for 1 month)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group, same duration as intervention)
Number of subjects: 24
Study: 18988907

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1489
Study: 17074343

Group type: EXPERIMENTAL
Intervention: Testicular samples pooled for cDNA microarray analysis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reverse transcription‐polymerase chain reaction (RT‐PCR)
Number of subjects: 24
Study: 15014412

Group type: COMPARATOR
Intervention: Halogen light curing for 20 seconds
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Plasma arc light curing for 5 seconds
Number of subjects: 83
Study: 11337296

Group type: EXPERIMENTAL
Intervention: 1% lidocaine injected lateral to the seminal vesicles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile normal saline injected lateral to the seminal vesicles
Number of subjects: 0
Study: 9075853

Group type: COMPARATOR
Intervention: CsA (n=50)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CsA-ME (n=51)
Number of subjects: 101
Study: 7950906

Group type: EXPERIMENTAL
Intervention: hGH measured after the marathon
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: hGH measured after recovery
Number of subjects: 7

Group type: COMPARATOR
Intervention: hGH measured in athletes vs controls after the marathon
Number of subjects: 7

Group type: COMPARATOR
Intervention: IGF-I measured in athletes and controls
Number of subjects: 7
Study: 3839111

Group type: EXPERIMENTAL
Intervention: Dazmegrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27466610

Group type: EXPERIMENTAL
Intervention: Pantawid conditional cash transfer program
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 485
Study: 24708702

Group type: EXPERIMENTAL
Intervention: Repeated abdominal amnioinfusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 56
Study: 22409782

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study: 19996310

Group type: EXPERIMENTAL
Intervention: Exercise only (12 wk of exercise without diet restriction)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (8 wk of very low energy diet 600 kcal/d followed by 4 wk with a weight maintenance diet)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and exercise (DEX; 8 wk very low energy diet 800 kcal/d followed by 4 wk weight maintenance diet combined with exercise throughout the 12 wk)
Number of subjects: 79
Study: 18542839

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 800

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 800
Study: 17457441

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily (n=72)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (n=73)
Number of subjects: 145
Study: 15520068

Group type: EXPERIMENTAL
Intervention: Combination cisplatin, interferon, doxorubicin and fluorouracil (PIAF)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Single-agent doxorubicin
Number of subjects: 102
Study: 10866893

Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (MAC) with propofol 50-100 microg/kg/min IV and remifentanil for pain control.
Number of subjects: 100

Group type: COMPARATOR
Intervention: General Anesthesia (GA) with propofol 1.5 mg/kg IV, remifentanil 0.125 microg/kg IV, maintained with desflurane (2%-4%) and nitrous oxide (60%).
Number of subjects: 100
Study: 9505980

Group type: EXPERIMENTAL
Intervention: Flunisolide 0.5 mg inhaled with and without oral charcoal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunisolide 1 mg, 2 mg, and 3 mg inhaled with concomitant charcoal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunisolide (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunisolide administered at 10 PM
Number of subjects: 0
Study: 1540717

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aortography
Number of subjects: 20
Study: 2860041

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 to 800 mg once daily for 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propranolol (160 to 320 mg twice daily for 12 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 45
Study: 30285519

Group type: EXPERIMENTAL
Intervention: SleepTrackTXT2 intervention (behavioral, non-pharmacological), additional text messages with recommendations for fatigue mitigation, weekly text messages promoting sleep.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 100
Study: 29219131

Group type: EXPERIMENTAL
Intervention: Early Childhood Education (ECE) activity
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: School readiness assessment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Physical facilities and classroom performance
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Supportive supervision and home environment
Number of subjects: 210
Study: 25840082

Group type: EXPERIMENTAL
Intervention: Tubeless mini-percutaneous nephrolithotomy (MPCNL)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (PCNL)
Number of subjects: 78
Study: 23061422

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV) among female source partners
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Higher plasma HIV‐1 in source partners
Number of subjects: 141
Study: 21978944

Group type: EXPERIMENTAL
Intervention: E2/DRSP (17β‐estradiol 1mg plus drospirenone 2mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 19775043

Group type: EXPERIMENTAL
Intervention: Customised APACHE II
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Customised SAPS II
Number of subjects: 2040
Study: 16546481

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 3.6 g/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (MP; 1.8 g/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Low-protein diet (LP; 0.8 g/kg)
Number of subjects: 5
Study: 12769147

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable lens (tisilfocon A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrogel lens (etafilcon A)
Number of subjects: 0
Study: 11086437

Group type: EXPERIMENTAL
Intervention: Group A: ADR, EPI, CDDP or 5‐FU alone (initially)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group B: CDDP 50 mg on day 1, 5‐FU 500 mg/day from day 2 to day 7 and 5‐FU 500 mg/day for 2 weeks thereafter (FP treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group C: CDDP 50 mg at reservoir insertion and 5‐FU 1,000 mg for 5 hours thereafter (WHF treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group D: 5‐FU 1,000 mg for 24 hours on day 1, day 3, and day 5 of every week with CDDP 5‐10 mg/day from day 1 to day 5 (intermittent F + low‐dose P treatment) for 3 weeks
Number of subjects: 49
Study: 9323551

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate injection (300 mg)
Number of subjects: 12
Study: 8405006

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 3899352

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 17
Study: 30359476

Group type: EXPERIMENTAL
Intervention: Vitamin D (adjusted to achieve a serum level > 30 ng/mL) with calcium (1,200 mg)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo with calcium (1,200 mg)
Number of subjects: 260
Study: 30589035

Group type: EXPERIMENTAL
Intervention: Thoracic duct ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonligation
Number of subjects: 60
Study: 27389564

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 654
Study: 24702522

Group type: EXPERIMENTAL
Intervention: SWIFT-Acute
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 22197003

Group type: EXPERIMENTAL
Intervention: 10mg of hydrocortisone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19713952

Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate-fat (MF) meal
Number of subjects: 10
Study: 18034852

Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Number of subjects: 93

Group type: COMPARATOR
Intervention: Toothbrush + floss
Number of subjects: 93
Study: 15869318

Group type: EXPERIMENTAL
Intervention: rAHF-PFM
Number of subjects: 0
Study: 11640942

Group type: EXPERIMENTAL
Intervention: Antiobsessive drug treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: OCD patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Patients with panic disorder
Number of subjects: 34
Study: 9846013

Group type: EXPERIMENTAL
Intervention: T‐PLL cases
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis
Number of subjects: 10
Study: 8608331

Group type: EXPERIMENTAL
Intervention: Train-the-trainer and consultation approach for 22 clinics
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group of 22 clinics left alone
Number of subjects: 44
Study: 2511700

Group type: EXPERIMENTAL
Intervention: Pentalong longo (40 mg PETN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentalong (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentalong longo (40 mg PETN) with five layers of coating
Number of subjects: 0
Study: 1071702

Group type: EXPERIMENTAL
Intervention: Special hypertension programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reference practices
Number of subjects: 100
Study: 30868790

Group type: EXPERIMENTAL
Intervention: LHW uncovered areas
Number of subjects: 102

Group type: COMPARATOR
Intervention: LHW covered areas
Number of subjects: 102
Study: 29141164

Group type: EXPERIMENTAL
Intervention: Lomustine plus Bevacizumab (combination group)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Lomustine alone (monotherapy group)
Number of subjects: 437
Study: 25956152

Group type: EXPERIMENTAL
Intervention: Sexually arousing visual stimuli (movie trailers, music video clips, and TV commercials)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nature documentary without sexual content (control group)
Number of subjects: 64
Study: 23992877

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (p.o. 150 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bevacizumab plus chemotherapy (gemcitabine/cisplatin or carboplatin/paclitaxel standard doses)
Number of subjects: 124
Study: 21236473

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy (RRH)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Total laparoscopic radical hysterectomy (TLRH)
Number of subjects: 1256
Study: 19425822

Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 16
Study: 17021714

Group type: EXPERIMENTAL
Intervention: Dipyridamole 400 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15104559

Group type: EXPERIMENTAL
Intervention: rhGH replacement therapy for 4 years
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGH replacement therapy + alendronate (10 mg/day) for 3 years
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group continuing on rhGH replacement alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: alendronate treatment
Number of subjects: 30
Study: 10646710

Group type: EXPERIMENTAL
Intervention: Virtual endoscopy (VE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Actual endoscopy
Number of subjects: 30
Study: 9764990

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg/day for 6 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 7836511

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg every 12 hours for five doses starting 4 days after LH surge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 0
Study: 2899719

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon at doses of 2.5, 5, or 10 X 10(6) U/m2 intramuscularly thrice weekly for 12‐24 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study: 31784746

Group type: EXPERIMENTAL
Intervention: Circulating triglycerides (TG) measured via log transformation of mg/dl data
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Genetic determinants of HbA1c
Number of subjects: 16000
Study: 29530067

Group type: EXPERIMENTAL
Intervention: Chance UK's mentoring programme
Number of subjects: 246

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 246
Study: 26901007

Group type: EXPERIMENTAL
Intervention: 0.5 g I/kg BW
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 0.4 g I/kg BW
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 0.3 g I/kg BW
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 25105787

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) with locking compression plate (LCP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intramedullary nailing (EHN)
Number of subjects: 49
Study: 22560729

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 177
Study: 19023658

Group type: EXPERIMENTAL
Intervention: Levo‐alpha‐acetylmethadol maintenance (LAAM)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Methadone maintenance (MM)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 315
Study: 17161535

Group type: EXPERIMENTAL
Intervention: Lamotrigine 400 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lamotrigine 300 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lamotrigine (pooled data)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lamotrigine (300 and 400 mg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 360
Study: 15815089

Group type: EXPERIMENTAL
Intervention: Neural network classifier using multispectral imaging system
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Neural network classifier using multispectral imaging system with additional set of 1022 lesions
Number of subjects: 1278
Study: 12297167

Group type: EXPERIMENTAL
Intervention: MECC system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 60
Study: 10445538

Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with oral bisacodyl (10 mg)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with one hypertonic phosphate enema
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with two hypertonic phosphate enemas
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral bisacodyl regimen
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral bisacodyl preparation
Number of subjects: 291
Study: 7847429

Group type: EXPERIMENTAL
Intervention: Growth hormone injections (0.05 mg/kg IBW for 28 days)
Number of subjects: 11
Study: 2111981

Group type: EXPERIMENTAL
Intervention: 25% albumin supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: No concentrated albumin (control)
Number of subjects: 40
Study: 387417

Group type: EXPERIMENTAL
Intervention: Pirbuterol 10 mg plus hydroxyzine 10 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pirbuterol 10 mg plus placebo
Number of subjects: 17